US 10,376,524 B2
Use of GABAA receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
Kathy P. Parker, Rochester, NY (US); David B. Rye, Dunwoody, GA (US); and Andrew Jenkins, Decatur, GA (US)
Assigned to Emory University, Atlanta, GA (US)
Filed by EMORY UNIVERSITY, Atlanta, GA (US)
Filed on Feb. 28, 2017, as Appl. No. 15/445,131.
Application 15/445,131 is a continuation of application No. 12/922,044, granted, now 9,616,070, previously published as PCT/US2009/037034, filed on Mar. 12, 2009.
Claims priority of provisional application 61/036,047, filed on Mar. 12, 2008.
Prior Publication US 2017/0196885 A1, Jul. 13, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/5517 (2006.01); A61K 31/70 (2006.01); A61K 9/08 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/5517 (2013.01) [A61K 9/006 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/20 (2013.01); A61K 31/70 (2013.01)] 19 Claims
 
1. A method of treating hypersomnia, the method comprising administering an effective amount of a GABAA receptor antagonist to a subject having hypersomnia, wherein the GABAA receptor antagonist is administered transmucosally or transdermally, and wherein the GABAA receptor antagonist is selected from the group consisting of flumazenil, clarithromycin, picrotoxin, bicuculline, cicutoxin, and oenanthotoxin.